Castle Biosciences Licenses IP for Thymoma Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Castle Biosciences said yesterday that it has licensed exclusive worldwide rights to intellectual property covering a gene expression profiling test for thymoma, rare tumors derived from the epithelial cells of the thymus gland.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.